FDA Approves Zymeworks’ Bispecific Antibody Ziihera, Licensed to Jazz Pharmaceuticals, for First-Line HER2+ Gastroesophageal Cancer

Zymeworks’ bispecific antibody Ziihera has received FDA approval for first-line treatment of HER2-positive gastroesophageal cancer. Discovered and engineered by Zymeworks using its Azymetric platform, Ziihera was licensed to Jazz Pharmaceuticals in 2022. The approval marks another milestone for the drug and expands its use in treating patients with HER2-positive cancers.